RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT05405309 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
5
Enrollment
OTHER
Sponsor class

Stopped This study was terminated due to sponsor de-activation of all programs associated with RP-3500 (camonsertib).

Conditions

Interventions

Sponsor

University of Utah

Collaborators